Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:57:06.696Z.
Calculation as of: 2026-10-06T15:57:06.696Z.
Quote observation: 2026-10-06T15:44:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f4beac4ac45f8a46ab4983c5a571fa9813be082d6d81805b5cbd768b9d0a60c
PE RATIO
N/A
Market Cap
$5.66M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.85M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.79M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.94M | 0.00 | 0.02 | 0.02 | 0.02 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.66M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.21M | N/A | 278.25 | 163.06 | 336.05 |
| Femasys Inc. (FEMY)vs › | $6.31M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.93
Forward EPS (Est.)
$-1.23
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
